Position in RPRX
as of Jun 30, 2026
· filed Jul 10, 2026
Position Value
$43,197,561
+$463,967 QoQ
Shares Held
770,422
-13.5% QoQ
Ownership
0.134%
of shares outstanding
% of Portfolio
0.72%
of 13F equity value
Holder Rank
#3
of 107 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 65%
Shared 0%
None 35%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WEDGE CAPITAL MANAGEMENT L L P/NC holds $146,192,500 across 9 Biotechnology names. RPRX ranks #1 (29.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
This page
|
770,422 | $43,197,561 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
403,824 | $31,607,304 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
126,539 | $30,492,102 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
47,775 | $29,789,623 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
82,530 | $3,004,917 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
23,422 | $2,600,544 | |
| 7 | TBPH |
Theravance Biopharma, Inc.
|
128,845 | $2,190,365 | |
| 8 | SVRA |
Savara Inc
|
294,215 | $1,812,364 |
All Filings in RPRX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $43,197,561 | 770,422 | Shares | Sole | 2026-07-10 | |
| 2026-03-31 | $42,733,594 | 890,840 | Shares | Sole | 2026-04-13 | |
| 2025-12-31 | $40,184,363 | 1,039,968 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $42,069,318 | 1,192,441 | Shares | Sole | 2025-10-10 | |
| 2025-06-30 | $43,773,603 | 1,214,921 | Shares | Sole | 2025-07-11 | |
| 2025-03-31 | $31,590,692 | 1,014,799 | Shares | Sole | 2025-04-14 | |
| No filing history on record for this holder in this stock. | ||||||